Novavax jumps 6% on cancer vaccine speculation, but real news is a new royalty model from partner approvals.

Novavax shares rose 6% amid retail trader speculation about its Matrix-M adjuvant being used in cancer vaccines. However, the actual significant development was a quiet announcement last week that its partners received approvals for the 2026-2027 seasonal COVID-19 vaccine formulation, making Novavax eligible for royalty payments without commercial infrastructure. This royalty model, tied to partner sales led by Sanofi and Takeda, offers a steady revenue stream, while oncology applications remain exploratory with no confirmed deals. Investors should focus on upcoming milestones tied to vaccine trials and manufacturing transfers rather than speculative oncology hopes.